Compare GRFS & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | HAE |
|---|---|---|
| Founded | 1940 | 1971 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.8B |
| IPO Year | 2008 | 1996 |
| Metric | GRFS | HAE |
|---|---|---|
| Price | $7.31 | $104.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $10.87 | ★ $111.50 |
| AVG Volume (30 Days) | 375.7K | ★ 455.3K |
| Earning Date | 07-28-2022 | 11-05-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $1.73 | $6.21 |
| Revenue Next Year | $6.26 | $5.54 |
| P/E Ratio | ★ $18.67 | $146.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.96 | $48.17 |
| 52 Week High | $10.16 | $110.45 |
| Indicator | GRFS | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 56.66 |
| Support Level | $7.21 | $100.53 |
| Resistance Level | $8.41 | $110.01 |
| Average True Range (ATR) | 0.10 | 2.49 |
| MACD | -0.00 | -0.77 |
| Stochastic Oscillator | 36.67 | 31.19 |
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.